http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105669860-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-90 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1009 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-10 |
| filingDate | 2016-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2019-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105669860-B |
| titleOfInvention | A kind of hand-foot-and-mouth disease resistant human immunoglobulin and preparation method thereof |
| abstract | The present invention relates to a kind of hand-foot-and-mouth disease resistant human immunoglobulin and preparation method thereof, hand-foot-and-mouth disease poison neutralize antibody titers are more than or equal to 1:800.The preparation method includes: that (1) filters out the efficient privilege blood plasma that hand-foot-and-mouth disease poison neutralize antibody titers are more than or equal to 1:80；(2) the efficient privilege blood plasma filtered out is mixed；(3) above-mentioned pooled plasma is separated and is tied ion exchange chromatography purifies and separates immunoglobulin components II using cold ethanol filter press technique, obtain the immunoglobulin of purity 98.5%~100% through filtering, chromatography, ultrafiltration, preparation, incubated at low pH inactivation of viruses, nano-film filtration removal virus, packing.Brothers mouthful human immunoglobulin(HIg) antibody titer, purity and the rate of recovery that the preparation and production method obtain are high, targetedly enterovirus can be treated, it is the active drug for treating enterovirus infection disease, securely and reliably, there is biggish Social benefit and economic benefit. |
| priorityDate | 2016-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 85.